The purpose of this study is to explore the feasibility of extending the dosing interval of
well maintained buprenorphine patients to 48 and 72 hours, leading to eventual 3 times/week
M/F ages 21-50. Opiate dependence according to DSM-IV critera. Self-reported use within
the last 30 days. Agreeable to conditions of study and signed informed consent.
Psychiatric disorder that requires medication therapy. History of seizures. Pregnant
and/or nursing women. Dependence on ETOH or benzodiazepines or other sedative-hynotics.
Acute hepatitis. Other medical conditions that deem participation to be unsafe.